Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity

Biochemical Journal

Volumn 370, Issue 3, 2003, Pages 921-926

  Flanagan, Jack U ^a   McLaughlin, Lesley A ^a   Paine, Mark J I ^a   Sutcliffe, Michael J ^b   Roberts, Gordon C K ^b   Wolf, C Roland ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Dextromethorphan; Diclofenac; Mutagenesis; P450; Tolbutamide

Indexed keywords

CARBOXYLATION; CATALYST ACTIVITY; CHROMOSOMES; ENZYMES; METABOLISM; SUBSTRATES;

ANTI-INFLAMMATORY COMPOUNDS;

ANTIBIOTICS;

ANTIDIABETIC AGENT; ASPARTIC ACID; CYTOCHROME P450 2C9; DEXTROMETHORPHAN; DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; TOLBUTAMIDE; ANTITUSSIVE AGENT; CYP2C9 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CATALYSIS; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME KINETICS; ENZYME SUBSTRATE; ESCHERICHIA COLI; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; STEADY STATE; AMINO ACID SEQUENCE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME SPECIFICITY; GENETICS; METABOLISM; MOLECULAR GENETICS; PROTEIN BINDING; PROTEIN SECONDARY STRUCTURE; RABBIT; SEQUENCE ALIGNMENT;

ESCHERICHIA COLI;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTITUSSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASPARTIC ACID; DEXTROMETHORPHAN; DICLOFENAC; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MUTAGENESIS, SITE-DIRECTED; NADPH-FERRIHEMOPROTEIN REDUCTASE; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RABBITS; SEQUENCE ALIGNMENT; SUBSTRATE SPECIFICITY; TOLBUTAMIDE;

EID: 0037443291     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20021841     Document Type: Article

References (41)

1. Guengerich, F. P. (1991) Reactions and significance of cytochrome P-450 enzymes. J. Biol. Chem. 266, 10019-10022
2. Gonzalez, F. J. (1990) Molecular genetics of the P-450 superfamily. Pharmacol. Ther. 45, 1-38
3. Nelson, D. R., Koymans, L, Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W. et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1-42
4. Miners, J. O. and Birkett, D. J. (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol. 45, 525-538
5. Smith, D. A. and Jones, B. C. (1992) Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem. Pharmacol. 44, 2089-2098
6. Guengerich, F. P. (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity Chem. Res. Toxicol. 14, 611-650
7. Srivastava, P. K., Yun, C. H., Beaune, P. H., Ged, C. and Guengerich, F. P. (1991) Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol. Pharmacol. 40, 69-79
8. Weaver, R. J., Dickins, M. and Burke, M. D. (1993) Cytochrome P450 269 is responsible for hydroxylation of the naphthoquinone antimalarial drug 58C80 in human liver. Biochem. Pharmacol. 46, 1183-1197
9. Leemann, T., Transon, C. and Dayer, P. (1993) Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci. 52, 29-34
10. Klose, T. S., Ibeanu, G. C., Ghanayem, B. I., Pedersen, L. G., Li, L., Hall, S. D. and Goldstein, J. A. (1998) Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. Arch. Biochem. Biophys. 357, 240-248
11. Mancy, A., Broto, P, Dijols, S., Dansette, P. M. and Mansuy, D. (1995) The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 34, 10365-10375
12. Williams, P. A., Cosme, J., Sridhar, V., Johnson, E. F. and McRee, D. E. (2000) Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell 5, 121-131
13. Ekins, S., de Groot, M. J. and Jones, J. P. (2001) Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. Drug Metab. Dispos. 29, 936-944
14. Lewis, D. F. (2000) On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human P450 substrate specificity and metabolism Biochem. Pharmacol. 60, 293-306
15. Mancy, A., Antignac, M., Minoletti, C., Dijols, S., Mouries, V., Duong, N. T., Battioni, P., Dansette, P. M. and Mansuy, D. (1999) Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry 38, 14264-14270
16. Ekins, S., Bravi, G., Binkley, S, Gillespie, J. S., Ring, B. J., Wikel, J. H. and Wrighton, S. A. (2000) Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab Dispos. 28, 994-1002
17. Strobl, G. R., von Kruedener, S, Stockigt, J., Guengedch, F. P. and Wolff, T. (1993) Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J. Med. Chem. 36, 1136-1145
18. Paine, M. J. I., McLaughlin., L. A., Flanagan, J. U., Kemp, C. A., Sutcliffe, M. J., Roberts, G. C. K. and Wolf, C. R. (2002) Residues glutamate-216 and aspartate-301 are key determinants of substrate specificity and product regiospecificity in cytochrome P450 2D6. J. Biol. Chem., in the press
19. Hanna, I. H., Kim, M. S. and Guengerich, F. P. (2001) Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity. Arch. Biochem Biophys. 393, 255-261
20. Ellis, S. W., Hayhurst, G. P., Smith, G., Lightfoot, T., Wong, M. M., Simula, A. P., Ackland, M. J., Sternberg, M. J., Lennard, M. S., Tucker, G. T. et al. (1995) Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J. Biol. Chem. 270, 29055-29058
21. Mackman, R., Tschirret-Guth, R. A., Smith, G., Hayhurst, G. P., Ellis, S. W., Lennard, M. S., Tucker, G. T., Wolf, C. R. and Ortiz de Montellano, P. R. (1996) Active-site topologies of human CYP2D6 and its aspartate-301 → glutamate, asparagine, and glycine mutants. Arch. Biochem. Biophys. 331, 134-140
22. Kirton, S. B., Kemp, C. A., Tomkinson, N. P., St-Gallay, S. and Sutcliffe, M. J. (2002) Impact of incorporating the 265 crystal structure into comparative models of cytochrome P450 2D6. Proteins 49, 216-231
23. Kunkel, T. A., Roberts, J. D. and Zakour, R. A. (1987) Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 154, 367-382
24. Pritchard, M. P., Glancey, M. J., Blake, J. A., Gilham, D. E., Burchell, B., Wolf, C. R. and Friedberg, T. (1998) Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli. Pharmacogenetics 8, 33-42
25. Blake, J. A., Pritchard, M., Ding, S., Smith, G. C., Burchell, B., Wolf, C. R. and Friedberg, T. (1996) Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli. FEBS Lett. 397, 210-214
26. Renaud, J. P., Peyronneau, M. A., Urban, P., Truan, G., Cullin, C., Pompon, D., Beaune, P. and Mansuy, D. (1993) Recombinant yeast in drug metabolism. Toxicology 82, 39-52
27. Omura, T. and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378
28. Komatsu, K., Ito, K., Nakajima, Y., Kanamitsu, S., Imaoka, S., Funae, Y., Green, C. E., Tyson, C. A., Shimada, N. and Sugiyama, Y. (2000) Prediction of in vivo drug - drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metab. Dispos. 28, 475-481
29. Masimirembwa, C. M., Otter, C., Berg, M., Jonsson, M., Leidvik, B., Jonsson, E., Johansson, T., Backman, A., Edlund, A. and Andersson, T. B. (1999) Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research. Drug Metab. Dispos. 27, 1117-1122
30. Yamazaki, H., Inoue, K. and Shimada, T. (1998) Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica 28, 103-115
31. Ridderstrom, M., Masimirembwa, C., Trump-Kallmeyer, S., Ahlefelt, M., Otter, C. and Andersson, T. B. (2000) Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. Biochem. Biophys. Res. Commun. 270, 983-987
32. Poli-Scaife, S., Attias, R., Dansette, P. M. and Mansuy, D. (1997) The substrate binding site of human liver cytochrome P450 2C9: an NMR study. Biochemistry 36, 12672-12682
33. Yu, A. and Haining, R. L. (2001) Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab. Dispos. 29, 1514-1520
34. Yu, A., Dong, H., Lang, D. and Haining, R. L. (2001) Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metab. Dispos. 29, 1362-1365
35. Guengerich, F. P., Miller, G. P., Hanna, I. H., Martin, M. V., Leger, S., Black, C., Chauret, N., Silva, J. M., Trimble, L. A., Yergey, J. A. et al. (2002) Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry 41, 11025-11034
36. Hasemann, C. A., Kurumbail, R. G., Boddupalli, S. S., Peterson, J. A. and Deisenhofer, J. (1995) Structure and function of cylochromes P450: a comparative analysis of three crystal structures. Structure 3, 41-62
37. Tsao, C. C., Wester, M. R., Ghanayem, B., Coulter, S. J., Chanas, B., Johnson, E. F. and Goldstein, J. A. (2001) Identification of human CYP2C19 residues that confer S-mephenytoin 4′-hydroxylation activity to CYP2C9. Biochemistry 40, 1937-1944
38. Gotoh, O. (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol. Chem. 267, 83-90
39. Oliver, C. F., Modi, S., Sutcliffe, M. J., Primrose, W. U., Lian, L. Y. and Roberts, G. C. (1997) A single mutation in cytochrome P450 BM3 changes substrate orientation in a catalylic intermediate and the regiospecificity of hydroxylation. Biochemistry 36, 1567-1572
40. Kronbach, T., Larabee, T. M. and Johnson, E. F. (1989) Hybrid cytochromes P-450 identify a substrate binding domain in P-45011C5 and P-45011C4. Proc. Natl. Acad. Sci. U.S.A. 86, 8262-8265
41. Thompson, J. D., Gibson, T. J. Plewniak, F., Jeanmougin, F. and Higgins, D. G. (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25, 4876-4882